Ovarian Cancer Clinical Trial

Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers

Summary

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

View Full Description

Full Description

OUTLINE: This is an observational study.

Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

* Subjects will have or had ovarian cancer and are on or have completed PARPi maintenance therapy

Or have been diagnosed with ovarian cancer as well as clonal hematopoiesis of indeterminate potential
Have a life expectancy of greater than 6 months

Exclusion Criteria:

* Individuals with a life expectancy of less than 6 months

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

2000

Study ID:

NCT06295965

Recruitment Status:

Recruiting

Sponsor:

University of Washington

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Fred Hutch/University of Washington Cancer Consortium
Seattle Washington, 98109, United States More Info
Swisher Lab Research Coordinators
Contact
206-616-8927
[email protected]
Elizabeth Swisher
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

2000

Study ID:

NCT06295965

Recruitment Status:

Recruiting

Sponsor:


University of Washington

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.